Last updated: July 31, 2026
ISOVUE-M 200 is Bracco Diagnostics’ intrathecal iopamidol formulation containing 200 mg iodine/mL. It is an established radiographic contrast agent for myelography and contrast-enhanced computed tomography of the central nervous system. The product is mature, with no active development program publicly associated with the marketed formulation, no meaningful branded-drug exclusivity remaining, and competition from generic iopamidol and other low-osmolar iodinated contrast agents. Its commercial outlook depends on hospital procurement, supply reliability, procedure volumes, and pricing rather than clinical differentiation.
What is ISOVUE-M 200 and what is it used for?
ISOVUE-M 200 contains iopamidol, a nonionic, water-soluble, low-osmolar iodinated contrast medium. Each milliliter contains 200 mg of organically bound iodine.
| Attribute |
ISOVUE-M 200 |
| Active ingredient |
Iopamidol |
| Iodine concentration |
200 mg iodine/mL |
| Dosage form |
Sterile injectable solution |
| Route |
Intrathecal |
| Primary manufacturer |
Bracco Diagnostics Inc. |
| Therapeutic category |
Diagnostic radiocontrast agent |
| Main procedures |
Myelography and selected CNS CT procedures |
| FDA regulatory pathway |
Approved new drug application |
| Biosimilar relevance |
None |
| Generic substitution risk |
High |
| Primary customers |
Hospitals, radiology departments and imaging centers |
The product label covers intrathecal administration for adult and pediatric patients undergoing radiographic procedures. Indications include cervical, thoracic, lumbar and total-column myelography, as well as contrast enhancement for CT cisternography and CT ventriculography where clinically appropriate.[1]
ISOVUE-M 200 is not intended for intravenous administration. Its intrathecal formulation and dosing requirements distinguish it from intravenous iopamidol products such as ISOVUE-300 and ISOVUE-370.
What is the FDA regulatory status of ISOVUE-M 200?
ISOVUE-M 200 is an FDA-approved prescription diagnostic product. The approval is based on iopamidol’s established safety and effectiveness as an intrathecal contrast medium. Its regulatory status is different from that of a conventional therapeutic drug because the product is used to improve visualization during imaging rather than to treat disease.
The label contains warnings concerning adverse neurologic reactions, including seizures, encephalopathy, aseptic meningitis-like reactions and other manifestations of contrast-induced neurotoxicity. Patients with seizure disorders, impaired blood-brain barrier function or other neurologic risk factors require particular clinical consideration.[1]
The product is administered by trained medical professionals. Dosing varies by procedure, anatomic region, patient age and imaging requirements. The prescribing information emphasizes use of the lowest effective dose and appropriate patient monitoring.
What is the Orange Book status of ISOVUE-M 200?
ISOVUE-M 200 is not generally treated as a commercially important Orange Book exclusivity product. Its original formulation approval dates to the mature era of iopamidol development, and any original composition, manufacturing or use patents would have expired long ago.
The commercial barriers are therefore regulatory and operational rather than patent-based. A competing manufacturer must establish pharmaceutical equivalence, product quality, sterility, stability and suitability for the intrathecal route. Those requirements can delay entry, but they do not provide long-term exclusivity comparable to an active formulation patent.
The FDA Orange Book should be checked for the current product-specific listing and any approved abbreviated new drug applications because listing status can change with ownership, discontinuation or manufacturing activity.[2]
Are there active clinical trials for ISOVUE-M 200?
No major active clinical development program for the marketed ISOVUE-M 200 formulation is publicly associated with the product. The clinical evidence base is mature and consists primarily of historical clinical studies, regulatory reviews and postmarketing safety data rather than modern pivotal trials.
ClinicalTrials.gov is not a reliable source of a current branded-product development pipeline for ISOVUE-M 200. Studies may identify iopamidol, myelography or intrathecal contrast media without naming the commercial product. A search for the brand should therefore be supplemented with searches for:
- Iopamidol
- Intrathecal iopamidol
- Myelography contrast
- CT cisternography contrast
- CT ventriculography contrast
- Nonionic intrathecal contrast media
The current clinical question is not whether ISOVUE-M 200 can obtain initial approval. It is whether the product retains a favorable safety and supply profile compared with alternative agents. New clinical research is more likely to evaluate imaging protocols, contrast-associated neurotoxicity, procedural safety or comparative use of contrast agents than to support a new indication for this specific brand.[3]
What patents protect ISOVUE-M 200?
No active, commercially material patent estate is expected to protect the core ISOVUE-M 200 product in the United States.
| Patent category |
Current commercial relevance |
| Iopamidol composition patents |
Expired |
| Original intrathecal-use patents |
Expired or no longer commercially material |
| Basic formulation patents |
Expected to be expired |
| Device patents |
Not central to the product |
| Manufacturing know-how |
Potentially relevant but not publicly equivalent to patent exclusivity |
| Current Orange Book patent protection |
No material branded protection identified |
Iopamidol is a long-established small-molecule contrast agent. Generic manufacturers can compete through abbreviated regulatory pathways if they meet FDA requirements for quality, strength, purity, sterility and labeling.
The remaining defensible assets are more likely to involve manufacturing controls, validated sterile processes, supplier relationships, inventory management and regulatory history. These assets can create execution advantages, but they do not block generic entry.
Which companies compete with ISOVUE-M 200?
ISOVUE-M 200 competes in two overlapping markets: intrathecal contrast media and the broader hospital iodinated-contrast market.
Direct and near-direct competitors
- Generic iopamidol products
- Iohexol products, including intrathecal formulations
- Iopromide and ioversol products where the approved route and procedure are comparable
- Other nonionic low-osmolar contrast agents used according to institutional protocols
Iohexol is the most relevant competitive reference because it has established intrathecal use and broad hospital distribution. Competition is usually determined by formulary position, contracted price, clinical familiarity and distributor availability.
How does ISOVUE-M 200 compare with iohexol?
| Factor |
ISOVUE-M 200 |
Iohexol intrathecal products |
| Active ingredient |
Iopamidol |
Iohexol |
| Product maturity |
Mature |
Mature |
| Clinical differentiation |
Limited |
Limited |
| Route |
Intrathecal |
Intrathecal |
| Generic competition |
High |
High |
| Main purchasing factor |
Price, supply and formulary status |
Price, supply and formulary status |
| Patent leverage |
Minimal |
Minimal |
| Switching barrier |
Institutional familiarity and protocol preference |
Institutional familiarity and protocol preference |
Neither product has a conventional high-growth pharmaceutical profile. A hospital may retain a preferred agent because of radiologist familiarity, existing order sets, safety protocols or group purchasing contracts. Those factors can preserve demand even when the underlying molecule is off patent.
What patent litigation and Paragraph IV challenges affect ISOVUE-M 200?
No major branded patent litigation or Paragraph IV dispute is associated with the core ISOVUE-M 200 product in the public record commonly used for pharmaceutical patent monitoring.
Paragraph IV litigation is less commercially significant for this product than for a recently approved therapeutic drug because:
- The core active ingredient is long established.
- Any original patent protection has expired.
- Generic contrast products can compete on a mature regulatory pathway.
- The market is driven by institutional procurement rather than consumer prescribing.
- The commercial value of litigating residual patent claims is limited.
Potential disputes would more likely involve manufacturing quality, regulatory exclusivity, labeling, supply contracts, product liability or intellectual property covering a delivery device or specialized formulation. Those issues should not be confused with a core composition patent blocking generic iopamidol.
When does ISOVUE-M 200 lose exclusivity?
ISOVUE-M 200 has already lost the exclusivity associated with its original active ingredient and initial product approval. There is no credible basis for projecting a new loss-of-exclusivity event comparable to the 2024-2030 patent cliffs affecting newer specialty drugs.
The commercial timeline is better described as follows:
| Period |
Commercial status |
| Original launch period |
Branded product protected by regulatory approval and any then-existing patents |
| Patent-expiration period |
Core iopamidol and original product protection expired |
| Current period |
Mature branded product competing with generic and alternative contrast agents |
| 2025-2030 |
Continued erosion risk, offset by supply, formulary and brand-recognition advantages |
The relevant question is not the date of patent expiry. It is whether Bracco can maintain contracted hospital volume and reliable supply at a price premium over generic alternatives.
What formulations are protected by ISOVUE-M 200?
The principal product distinction is its intrathecal formulation at 200 mg iodine/mL. The formulation is designed for administration into the cerebrospinal fluid and differs from higher-concentration intravenous products.
The formulation’s commercial value comes from:
- Sterile injectable presentation
- Intrathecal labeling
- Controlled iodine concentration
- Established compatibility with myelographic procedures
- Regulatory history and physician familiarity
- Bracco’s manufacturing and distribution infrastructure
These attributes may create a practical switching barrier. They do not create meaningful modern patent exclusivity unless supported by an unexpired claim, which is not expected for the core product.
What is the market outlook for ISOVUE-M 200?
ISOVUE-M 200 belongs to a mature, low-growth diagnostic contrast segment. Demand is linked to the number of myelography and related CNS imaging procedures, not to chronic patient treatment.
Demand drivers
- Aging populations with spinal stenosis and degenerative spine disease
- Continued use of myelography when MRI is contraindicated, unavailable or clinically insufficient
- Growth in image-guided procedures
- Hospital replacement of older contrast inventory
- Supply disruptions affecting competing products
Demand constraints
- MRI substitution in many CNS diagnostic pathways
- Declining use of conventional myelography in some institutions
- Generic pricing pressure
- Hospital purchasing consolidation
- Limited physician switching incentives
- Low product differentiation
A precise global revenue forecast for ISOVUE-M 200 is not publicly disclosed. Bracco reports at the company level rather than providing a separate revenue line for this individual strength and presentation. A defensible projection therefore requires a bottom-up model based on procedure volume, market share, net price and supply performance rather than a reported product forecast.
2025-2030 scenario projection
| Scenario |
Procedure demand |
Branded share |
Net price trend |
Revenue outlook |
| Downside |
Declines 4%-6% annually |
Falls rapidly |
Declines 5%-8% annually |
High-single- to low-double-digit annual decline |
| Base case |
Flat to down 1%-2% annually |
Gradual erosion |
Declines 2%-4% annually |
Mid-single-digit annual decline |
| Upside |
Grows 1%-2% annually |
Stable in contracted accounts |
Flat to down 2% annually |
Flat to modest annual growth |
The base case is the most supportable commercial view. ISOVUE-M 200 should be modeled as a stable but declining hospital product, with periodic volume gains during competitor shortages. The product is unlikely to generate material growth from new indications or clinical innovation.
What generic launch risks exist for ISOVUE-M 200?
Generic launch risk is high in principle but may be moderate in realized commercial impact because the relevant market is specialized and procurement-driven.
Regulatory barriers
Generic entrants must demonstrate:
- Sterility and injectable product quality
- Consistent iopamidol concentration
- Adequate stability and container closure integrity
- Intrathecal suitability
- Manufacturing compliance
- Labeling aligned with the approved route and indications
Commercial barriers
The main barriers are:
- Limited market size
- Hospital contracting requirements
- Group purchasing organization access
- Need for reliable sterile manufacturing
- Distributor qualification
- Physician and radiology-department familiarity
- Inventory and shortage-management requirements
A generic entrant could obtain regulatory approval yet fail to capture substantial share if it cannot support national distribution or hospital contract pricing.
Does ISOVUE-M 200 face biosimilar risk?
No. Biosimilars apply to biological products. Iopamidol is a chemically synthesized small molecule. ISOVUE-M 200 faces generic-drug competition, not biosimilar competition.
What licensing deals affect ISOVUE-M 200?
No major recent licensing transaction is publicly linked specifically to ISOVUE-M 200. Bracco’s commercial position is primarily based on ownership, manufacturing and distribution of its contrast-media portfolio rather than a newly licensed technology protecting this individual product.
A licensing or supply arrangement involving iopamidol, a contract manufacturer or a distributor could affect availability without changing the patent status. Such agreements are generally not disclosed at the individual product-strength level.
How strong is the ISOVUE-M 200 patent estate?
The patent estate is weak as a current exclusivity tool and moderate as a historical regulatory and manufacturing platform.
| Patent-estate factor |
Assessment |
| Core molecule protection |
Expired |
| Core intrathecal use protection |
Expired or immaterial |
| New formulation protection |
No material current protection identified |
| Orange Book leverage |
Low |
| Litigation leverage |
Low |
| Manufacturing know-how |
Moderate operational value |
| Brand and hospital relationships |
Moderate commercial value |
| Supply-chain advantage |
Potentially material during shortages |
Key Takeaways
- ISOVUE-M 200 is an established intrathecal iopamidol product from Bracco Diagnostics.
- Its primary uses are myelography and selected CNS CT procedures.
- No active product-specific clinical development program is publicly associated with the marketed formulation.
- The core molecule and original product protections are expired.
- No material current Orange Book patent or Paragraph IV litigation issue drives the product outlook.
- Generic iopamidol and iohexol are the main competitive threats.
- The product is exposed to gradual price and share erosion, but hospital contracts and supply reliability can preserve volume.
- A base-case 2025-2030 model supports mid-single-digit annual revenue decline rather than a sharp patent-cliff collapse.
- The main commercial risks are generic substitution, MRI displacement, procurement pressure and sterile-product supply competition.
- ISOVUE-M 200 has generic risk, not biosimilar risk.
FAQs About ISOVUE-M 200
Is ISOVUE-M 200 still available?
It is an established marketed product, but availability can vary by country, presentation, distributor inventory and hospital contract. Product-specific supply status should be verified through current FDA and manufacturer channels.
Is ISOVUE-M 200 the same as intravenous ISOVUE?
No. ISOVUE-M 200 is labeled for intrathecal use. Intravenous ISOVUE products use different concentrations and approved administration routes.
Can generic iopamidol replace ISOVUE-M 200?
A generic product may be substitutable when it has the appropriate FDA approval, labeling, concentration, route and institutional formulary status. Substitution is controlled by hospital policy and clinical judgment.
Is ISOVUE-M 200 used for MRI?
No. ISOVUE-M 200 is an iodinated X-ray and CT contrast agent. MRI contrast agents generally use gadolinium-based compounds or other MRI-specific technologies.
Why would physicians use ISOVUE-M 200 instead of MRI?
Myelography may be used when MRI is contraindicated, unavailable, technically inadequate or insufficient for the clinical question. It can provide dynamic or high-resolution information about the spinal canal and nerve-root structures.
References
- Bracco Diagnostics Inc. (2023). ISOVUE-M (iopamidol injection) prescribing information. U.S. Food and Drug Administration/DailyMed.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. National Library of Medicine. (2024). ClinicalTrials.gov: Search results for iopamidol, intrathecal contrast and myelography.
- Bracco Diagnostics Inc. (2024). Contrast media product information and clinical resources.
- U.S. Food and Drug Administration. (2024). Drug shortages and supply-chain information for sterile injectable products.
